Youn H Kim
Academic Appointments
- Professor - Med Center Line, Dermatology
- Member, Stanford Cancer Institute
- Professor - Med Center Line (By courtesy), Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Cancer Center 875 Blake Wilbur Drive Clinic A Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 721-2521Cutaneous Oncology 900 Blake Wilbur Drive, MC 5356 Office W1010 Stanford, CA 94305 Tel Work (650) 725-3292 Fax (650) 725-6937
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Cutaneous (Dermatologic) Oncology
- Cutaneous Lymphoma
- Cutaneous Lymphoma - Dermatology
- Dermatology
- Mycosis Fungoides
Administrative Appointments
- Director, Multi-disciplinary Cutaneous Lymphoma Program, Stanford University Medical Center (2004 - present)
- Director, Residency Program, Department of Dermatology, Stanford University Medical Center (2004 - present)
- Medical Director, Photopheresis Unit, Stanford University Medical Center (2004 - present)
Honors and Awards
- Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2001)
- Distinguished Service Award, Department of Dermatology, Stanford University School of Medicine (1995)
- The Best Doctors in America: Pacific Region, Woodward/White, Inc (1996-)
Professional Education
| Board Certification: | Dermatology, American Board of Dermatology (1989) |
| Residency: | SUMC - Graduate Medical Education CA (1989) |
| Internship: | Kaiser - San Francisco (1985) |
| Medical Education: | Stanford University School of Medicine CA (1984) |
| Doctor of Medicine: | Stanford University, Medicine (1984) |
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Clinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
Clinical Trials
- Phase I/II Low-dose (12 Gy) TSEBT+Vorinostat VS Low-dose TSEBT Monotherapy in Mycosis Fungoides Recruiting
- Phase IB Topical SHP-141 in Stage IA, IB, or IIA Cutaneous T-Cell Lymphoma Recruiting
- Pilot Study of Brentuximab Vedotin (SGN-35) in Patients with MF with Variable CD30 Expression Level Recruiting
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
Publications
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012; (2): 355-63
- Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011; (4): e651-7
- Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; (29): 4485-91
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; (28): 4324-32
- Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009; (6): 667-74
Help